Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Gambhir brings over 35 years of rich experience in strategic finance, governance, business transformation, and leadership
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
Certification reinforces energy efficiency, sustainability goals, and green manufacturing across SMT’s Surat and Hyderabad facilities
Subscribe To Our Newsletter & Stay Updated